Introduction
============

Disease severity varies widely in patients with severe sepsis. Previous trials (IL-1RA, TNF-sR p55, antithrombin, and drotrecogin alfa activated (DAA)) suggest that more severely ill patients benefit most from treatment.

Objective
=========

The aim of this study was to evaluate the efficacy of eritoran for interaction effects with baseline illness severity.

Methods
=======

Prospective covariates from a randomized, double-blind, placebo-controlled, phase 2 trial were analyzed for treatment interaction measured by 28-day mortality. Breslow-Day and multiple logistic regression (LR) were used to assess categorical (CAT) and continuous (CONT) treatment by severity-of-illness interactions.

Results
=======

Modified intent-to-treat population (n = 292) all-cause 28-day mortality was: placebo, 33.3% (32/96); total eritoran 45 mg/105 mg, 29.6% (58/196). LR analysis identified Acute Physiology and Chronic Health Evaluation (APACHE) II scores, Predicted Risk of Mortality (PROM) scores, IL-6, age, sex, race, and eritoran as associated with survival outcomes. Significant treatment interactions were observed (eritoran vs. placebo) for baseline covariates: APACHE II (CAT, *P*= 0.059; CONT, *P*= 0.035); PROM scores (CAT, *P*= 0.028; CONT, *P*= 0.008); number of organ failures (CAT, *P*= 0.079); international normalized ratio (CAT, *P*= 0.05); and acute physiology score (CONT, *P*= 0.039). No significant treatment interactions were observed with age, sex, shock, DAA use, infection site, microorganism type, platelets, IL-6, or endotoxin levels. Interaction results were similar for eritoran 105 mg only versus placebo.

Conclusion
==========

Potential survival benefits of eritoran in severe sepsis patients may be associated with high severity of illness. Treatment by disease severity interaction will be further explored in a phase 3 trial.
